0:00 / 0:00
Comparing treatments for macular degeneration: findings and impact
Cochrane
14K subscribers • 30 videos on Rounds • Health institution
- Published by Cochrane, one of the health institutions Rounds lists. Nobody has recommended it in the communities yet, so it ranks below community picks.
- May be out of date. Uploaded 11 years ago, in an area where guidance changes.
Assumes interest and some biology. Education, not medical advice.
3.5K views11 years ago
Medicines and supplementsEvidence and public healthHow drugs workReading studies
An explanation of a Cochrane review comparing the safety and efficacy of bevacizumab and ranibizumab for macular degeneration.
This video tells the story of a Cochrane review which compared two treatments for macular degeneration - bevacizumab (brand name Avastin®) and intravitreal ranibizumab (brand name Lucentis®). It represents an important step forward in the knowledge about differences in systemic harms between these two drugs. Find out more about why, along with one story of how this Cochrane review has already made a difference. Read the review here: cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011230.pub2/…Why it's here
From a health institutionCochrane is on Rounds' list of health institutions, and this upload is one of its most-watched lectures or explainers. Nobody has recommended it in the communities yet, so it ranks below community picks.